|
Oct 3
|
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
|
|
Oct 1
|
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
|
|
Aug 27
|
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
|
|
Jun 26
|
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
|
|
Jun 19
|
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
|
Mar 19
|
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
|
|
Mar 18
|
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
|
|
Feb 7
|
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
|
|
Jan 28
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Jan 23
|
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
|
|
Nov 30
|
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
|